Amicus Therapeutics Stock Price, News & Analysis (NASDAQ:FOLD)

$12.85 -0.05 (-0.39 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$12.85
Today's Range$12.72 - $13.04
52-Week Range$4.41 - $16.60
Volume3.45 million shs
Average Volume3.14 million shs
Market Capitalization$2.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.76

About Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics logoAmicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.

Receive FOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:FOLD
CUSIP03152W10
Phone609-662-2000

Debt

Debt-to-Equity Ratio0.39%
Current Ratio6.32%
Quick Ratio6.22%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.96 million
Price / Sales430.76
Cash FlowN/A
Price / CashN/A
Book Value$2.52 per share
Price / Book5.10

Profitability

Trailing EPS($1.83)
Net Income$-200,040,000.00
Net Margins-1,092.37%
Return on Equity-63.54%
Return on Assets-23.46%

Miscellaneous

Employees263
Outstanding Shares166,270,000

Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.10. The biopharmaceutical company earned $10.90 million during the quarter, compared to the consensus estimate of $9.02 million. Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The company's revenue for the quarter was up 419.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.33) EPS. View Amicus Therapeutics' Earnings History.

When will Amicus Therapeutics make its next earnings announcement?

Amicus Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Amicus Therapeutics.

Where is Amicus Therapeutics' stock going? Where will Amicus Therapeutics' stock price be in 2017?

7 analysts have issued 1-year price objectives for Amicus Therapeutics' shares. Their forecasts range from $15.00 to $20.00. On average, they anticipate Amicus Therapeutics' stock price to reach $18.07 in the next twelve months. View Analyst Ratings for Amicus Therapeutics.

What are Wall Street analysts saying about Amicus Therapeutics stock?

Here are some recent quotes from research analysts about Amicus Therapeutics stock:

  • 1. According to Zacks Investment Research, "AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. " (10/12/2017)
  • 2. Cowen Inc analysts commented, "This morning, FOLD announced that after more recent FDA talks and written." (7/11/2017)

Are investors shorting Amicus Therapeutics?

Amicus Therapeutics saw a increase in short interest in November. As of November 30th, there was short interest totalling 30,838,848 shares, an increase of 3.1% from the November 15th total of 31,828,823 shares. Based on an average daily trading volume, of 1,627,415 shares, the short-interest ratio is currently 18.9 days. Currently, 19.2% of the company's stock are short sold.

Who are some of Amicus Therapeutics' key competitors?

Who are Amicus Therapeutics' key executives?

Amicus Therapeutics' management team includes the folowing people:

  • John F. Crowley J.D., Chairman of the Board, Chief Executive Officer (Age 50)
  • Bradley L. Campbell, President, Chief Operating Officer (Age 41)
  • William D. Baird III, Chief Financial Officer (Age 45)
  • Daphne E. Quimi, Senior Vice President - Finance and Administration, Corporate Controller (Age 51)
  • Kurt J. W. Andrews, Senior Vice President - Human Resources (Age 48)
  • Hung Viet Do, Chief Scientific Officer (Age 49)
  • Ellen S. Rosenberg, General Counsel and Corporate Secretary (Age 54)
  • Jay A. Barth M.D., Chief Medical Officer (Age 53)
  • Donald J. Hayden Jr., Lead Independent Director (Age 61)
  • Robert A. Essner, Independent Director (Age 70)

Who owns Amicus Therapeutics stock?

Amicus Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (10.76%), Jennison Associates LLC (5.94%), Janus Henderson Group PLC (4.47%), Eagle Asset Management Inc. (1.64%), Victory Capital Management Inc. (1.51%) and Sectoral Asset Management Inc (1.45%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Life Sciences Maste Perceptive, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.

Who sold Amicus Therapeutics stock? Who is selling Amicus Therapeutics stock?

Amicus Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Point72 Asset Management L.P., Sectoral Asset Management Inc, AXA, Candriam Luxembourg S.C.A., Prudential Financial Inc., Asymmetry Capital Management L.P. and BNP Paribas Arbitrage SA. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Hung Do, Jay Barth, John F Crowley, Michael Raab and William D Baird III. View Insider Buying and Selling for Amicus Therapeutics.

Who bought Amicus Therapeutics stock? Who is buying Amicus Therapeutics stock?

Amicus Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Jennison Associates LLC, Allianz Asset Management GmbH, Perceptive Advisors LLC, Janus Henderson Group PLC, Bank of New York Mellon Corp, Cowen Inc. and Schwab Charles Investment Management Inc.. Company insiders that have bought Amicus Therapeutics stock in the last two years include Ellen Rosenberg, John F Crowley, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics.

How do I buy Amicus Therapeutics stock?

Shares of Amicus Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amicus Therapeutics' stock price today?

One share of Amicus Therapeutics stock can currently be purchased for approximately $12.85.

How big of a company is Amicus Therapeutics?

Amicus Therapeutics has a market capitalization of $2.16 billion and generates $4.96 million in revenue each year. The biopharmaceutical company earns $-200,040,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. Amicus Therapeutics employs 263 workers across the globe.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]


MarketBeat Community Rating for Amicus Therapeutics (FOLD)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  271 (Vote Outperform)
Underperform Votes:  144 (Vote Underperform)
Total Votes:  415
MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Amicus Therapeutics (NASDAQ:FOLD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.862.862.88
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.07$18.07$14.36$11.94
Price Target Upside: 13.09% upside13.09% upside3.44% upside40.13% upside

Amicus Therapeutics (NASDAQ:FOLD) Consensus Price Target History

Price Target History for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ:FOLD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017Goldman Sachs GroupReiterated RatingNeutral -> Neutral$17.00N/AView Rating Details
10/5/2017Chardan CapitalReiterated RatingBuy$16.50 -> $18.50N/AView Rating Details
10/4/2017Robert W. BairdReiterated RatingOutperform$16.00 -> $18.00N/AView Rating Details
10/4/2017J P Morgan Chase & CoReiterated RatingOverweightN/AView Rating Details
10/4/2017Leerink SwannReiterated RatingBuy$17.00 -> $20.00MediumView Rating Details
10/4/2017Bank of AmericaBoost Price TargetBuy$15.00 -> $20.00HighView Rating Details
9/14/2017CowenReiterated RatingOutperform$16.00 -> $18.00LowView Rating Details
3/8/2016Janney Montgomery ScottUpgradeNeutral -> Buy$10.00 -> $12.00N/AView Rating Details
(Data available from 12/16/2015 forward)

Earnings

Amicus Therapeutics (NASDAQ:FOLD) Earnings History and Estimates Chart

Earnings by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ FOLD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018($0.29)N/AView Earnings Details
11/8/2017Q3 2017($0.31)($0.41)$9.02 million$10.90 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.37)($0.34)$6.96 million$7.16 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.37)($0.39)$4.16 million$4.20 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.33)($0.32)$3.16 million$2.83 millionViewListenView Earnings Details
11/7/2016Q3($0.31)($0.33)$1.71 million$2.10 millionViewListenView Earnings Details
8/9/2016Q2($0.33)($0.40)$0.17 millionViewN/AView Earnings Details
5/3/2016Q1($0.34)($0.35)ViewListenView Earnings Details
11/3/2015Q3($0.25)($0.32)ViewN/AView Earnings Details
8/5/2015Q215($0.24)($0.26)ViewN/AView Earnings Details
5/5/2015Q115($0.14)($0.25)$0.50 millionViewN/AView Earnings Details
3/3/2015Q414($0.18)($0.24)$0.48 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.21)($0.22)$1.00 million$0.29 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.24)($0.23)$0.48 millionViewN/AView Earnings Details
5/5/2014Q1 2014($0.23)($0.25)$0.20 million$0.46 millionViewN/AView Earnings Details
3/3/2014Q4 13($0.32)($0.22)$0.32 millionViewN/AView Earnings Details
11/11/2013Q3($0.32)($0.29)ViewN/AView Earnings Details
8/7/2013Q2 2013($0.35)($0.31)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.30)($0.34)ViewN/AView Earnings Details
11/5/2012Q312($0.24)($0.31)$8.82 million$5.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Amicus Therapeutics (NASDAQ:FOLD) Earnings Estimates

2017 EPS Consensus Estimate: ($1.38)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.39)($0.39)($0.39)
Q2 20171($0.35)($0.35)($0.35)
Q3 20171($0.30)($0.30)($0.30)
Q4 20171($0.34)($0.34)($0.34)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Amicus Therapeutics (NASDAQ:FOLD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Amicus Therapeutics (NASDAQ FOLD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.40%
Insider Trades by Quarter for Amicus Therapeutics (NASDAQ:FOLD)
Insider Trades by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ FOLD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/11/2017John F CrowleyCEOSell12,206$13.52$165,025.12View SEC Filing  
12/4/2017John F CrowleyCEOSell47,213$13.61$642,568.93View SEC Filing  
12/1/2017Jay BarthInsiderSell5,000$13.59$67,950.00View SEC Filing  
10/18/2017John F CrowleyCEOSell71,735$14.75$1,058,091.25View SEC Filing  
10/16/2017John F CrowleyCEOSell449,295$14.33$6,438,397.35View SEC Filing  
10/12/2017Daphne QuimiSVPSell7,000$14.25$99,750.00View SEC Filing  
10/12/2017Hung DoInsiderSell50,194$14.25$715,264.50View SEC Filing  
10/12/2017Michael RaabDirectorSell10,000$14.25$142,500.00View SEC Filing  
10/12/2017William D Baird IIICFOSell40,000$14.25$570,000.00View SEC Filing  
9/26/2017John F CrowleyCEOBuy1,395$14.36$20,032.20View SEC Filing  
7/13/2017Life Sciences Maste PerceptiveMajor ShareholderBuy1,500,000$12.25$18,375,000.00View SEC Filing  
6/19/2017Jay BarthInsiderSell30,000$10.00$300,000.00View SEC Filing  
5/19/2017Hung DoInsiderSell29,914$8.00$239,312.00View SEC Filing  
3/2/2017Bradley L CampbellCOOSell49,050$8.00$392,400.00View SEC Filing  
1/13/2017Hung DoInsiderSell25,000$6.00$150,000.00View SEC Filing  
12/30/2016Perceptive Advisors LlcMajor ShareholderBuy94,750$4.96$469,960.00View SEC Filing  
12/29/2016Perceptive Advisors LlcMajor ShareholderBuy142,125$4.87$692,148.75View SEC Filing  
12/23/2016Perceptive Advisors LlcMajor ShareholderBuy85,275$4.81$410,172.75View SEC Filing  
12/22/2016Perceptive Advisors LlcMajor ShareholderBuy189,500$4.51$854,645.00View SEC Filing  
11/9/2016Daphne QuimiSVPSell8,546$8.00$68,368.00View SEC Filing  
11/1/2016Hung DoInsiderSell25,000$7.00$175,000.00View SEC Filing  
10/3/2016Hung DoInsiderSell25,000$7.25$181,250.00View SEC Filing  
9/20/2016William D Baird IIICFOSell20,500$8.00$164,000.00View SEC Filing  
9/6/2016Hung DoInsiderSell25,000$7.00$175,000.00View SEC Filing  
8/25/2016Perceptive Advisors LlcInsiderSell1,100,000$6.81$7,491,000.00View SEC Filing  
8/4/2016Jay BarthInsiderSell10,458$7.00$73,206.00View SEC Filing  
7/27/2016Jay BarthInsiderSell20,916$7.00$146,412.00View SEC Filing  
6/2/2016Ellen RosenbergGeneral CounselBuy15,000$7.67$115,050.00View SEC Filing  
11/10/2015Margaret G McglynnDirectorBuy10,000$10.27$102,700.00View SEC Filing  
10/7/2015Perceptive Advisors LlcMajor ShareholderBuy50,000$6.27$313,500.00View SEC Filing  
10/6/2015Perceptive Advisors LlcMajor ShareholderBuy750,000$6.71$5,032,500.00View SEC Filing  
10/1/2015Kenneth PeistVPSell10,000$13.14$131,400.00View SEC Filing  
9/21/2015Bradley L. CampbellCOOSell13,001$16.78$218,156.78View SEC Filing  
9/21/2015William D. Baird IIICFOSell15,236$16.78$255,660.08View SEC Filing  
9/15/2015Hung DoInsiderSell25,000$17.75$443,750.00View SEC Filing  
9/14/2015Daphne QuimiVPSell2,500$18.08$45,200.00View SEC Filing  
7/16/2015John F CrowleyCEOSell16,025$16.00$256,400.00View SEC Filing  
7/14/2015John F CrowleyCEOSell142,250$15.03$2,138,017.50View SEC Filing  
7/13/2015Glenn SblendorioDirectorSell10,000$15.00$150,000.00View SEC Filing  
7/13/2015John F CrowleyCEOSell7,750$15.01$116,327.50View SEC Filing  
7/13/2015Ken ValenzanoSVPSell15,000$15.00$225,000.00View SEC Filing  
7/8/2015Dipal DoshiSVPSell6,250$13.87$86,687.50View SEC Filing  
7/1/2015Jayne GershkowitzSVPSell10,649$13.97$148,766.53View SEC Filing  
7/1/2015Kenneth PeistVPSell10,000$13.98$139,800.00View SEC Filing  
6/23/2015Donald J Hayden JrDirectorSell55,000$14.01$770,550.00View SEC Filing  
6/22/2015Jeff CastelliSVPSell18,981$13.94$264,595.14View SEC Filing  
6/19/2015Bradley L CampbellCOOSell13,000$13.26$172,380.00View SEC Filing  
6/19/2015Enrique DiloneSVPSell14,045$13.26$186,236.70View SEC Filing  
6/19/2015William D Baird IIICFOSell15,235$13.26$202,016.10View SEC Filing  
6/15/2015Jeff CastelliSVPSell7,377$14.17$104,532.09View SEC Filing  
6/15/2015Julie YuVPSell8,195$14.17$116,123.15View SEC Filing  
6/8/2015Jeff CastelliSVPSell17,312$12.87$222,805.44View SEC Filing  
6/8/2015John F CrowleyCEOSell55,000$13.01$715,550.00View SEC Filing  
5/11/2015Jeff CastelliSVPSell10,000$10.84$108,400.00View SEC Filing  
5/11/2015Kenneth PeistVPSell12,500$10.84$135,500.00View SEC Filing  
5/11/2015William D Baird IIICFOSell24,800$10.84$268,832.00View SEC Filing  
4/15/2015Glenn SblendorioDirectorSell20,000$12.50$250,000.00View SEC Filing  
4/15/2015Ken ValenzanoVPSell5,000$12.50$62,500.00View SEC Filing  
4/10/2015John F CrowleyCEOSell11,678$12.00$140,136.00View SEC Filing  
4/1/2015Jeff CastelliVPSell9,489$10.69$101,437.41View SEC Filing  
1/5/2015Jeff CastelliVPSell4,667$9.00$42,003.00View SEC Filing  
12/4/2014John F CrowleyCEOSell89,000$8.36$744,040.00View SEC Filing  
11/25/2014Bradley L CampbellCOOSell7,250$8.00$58,000.00View SEC Filing  
11/25/2014Jeff CastelliVPSell8,103$8.00$64,824.00View SEC Filing  
11/25/2014William D Baird IIICFOSell10,000$8.00$80,000.00View SEC Filing  
11/19/2014Perceptive Advisors LlcMajor ShareholderBuy2,100,000$6.50$13,650,000.00View SEC Filing  
10/27/2014Plc GlaxosmithklineMajor ShareholderSell11,315,825$5.29$59,860,714.25View SEC Filing  
10/3/2014Jeff CastelliVPSell8,552$7.00$59,864.00View SEC Filing  
10/3/2014William D Baird IIICFOSell10,000$7.00$70,000.00View SEC Filing  
10/2/2014Julie YuVPSell4,759$5.99$28,506.41View SEC Filing  
9/29/2014Daphne QuimiVPSell10,738$6.10$65,501.80View SEC Filing  
9/29/2014William D Baird IIICFOSell25,311$6.09$154,143.99View SEC Filing  
8/27/2014Glenn SblendorioDirectorSell10,000$6.50$65,000.00View SEC Filing  
8/27/2014Jayne GershkowitzVPSell5,000$7.00$35,000.00View SEC Filing  
8/25/2014Bradley L CampbellCOOSell7,000$6.00$42,000.00View SEC Filing  
8/25/2014Jayne GershkowitzVPSell5,000$6.00$30,000.00View SEC Filing  
8/20/2014Bradley L CampbellCOOSell18,750$5.40$101,250.00View SEC Filing  
8/20/2014Enrique DiloneVPSell12,810$5.40$69,174.00View SEC Filing  
6/30/2014Perceptive Advisors LlcMajor ShareholderBuy4,000,000$3.50$14,000,000.00View SEC Filing  
11/20/2013Plc Glaxosmithklinemajor shareholderBuy1,500,000$2.00$3,000,000.00View SEC Filing  
3/15/2013Sol J BarerDirectorBuy25,000$3.40$85,000.00View SEC Filing  
11/13/2012Joan WinterbottomSVPBuy1,665$4.54$7,559.10View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Amicus Therapeutics (NASDAQ FOLD) News Headlines

Source:
DateHeadline
This Tiny Biotech Pins Hope on U.S. ApprovalThis Tiny Biotech Pins Hope on U.S. Approval
finance.yahoo.com - December 15 at 5:53 PM
Amicus Therapeutics (FOLD) Submits NDA for Migalastat in Fabry Disease - StreetInsider.comAmicus Therapeutics (FOLD) Submits NDA for Migalastat in Fabry Disease - StreetInsider.com
www.streetinsider.com - December 15 at 9:57 AM
-$0.30 EPS Expected for Amicus Therapeutics, Inc. (FOLD) This Quarter-$0.30 EPS Expected for Amicus Therapeutics, Inc. (FOLD) This Quarter
www.americanbankingnews.com - December 14 at 7:50 PM
Amicus Therapeutics Submits New Drug Application to U.S. FDA for Migalastat for Treatment of Fabry DiseaseAmicus Therapeutics Submits New Drug Application to U.S. FDA for Migalastat for Treatment of Fabry Disease
finance.yahoo.com - December 14 at 9:39 AM
Amicus Therapeutics, Inc. (FOLD) CEO Sells $165,025.12 in StockAmicus Therapeutics, Inc. (FOLD) CEO Sells $165,025.12 in Stock
www.americanbankingnews.com - December 13 at 6:22 PM
Amicus Therapeutics, Inc. (FOLD) Receives Consensus Rating of "Buy" from BrokeragesAmicus Therapeutics, Inc. (FOLD) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 11 at 3:38 AM
BidaskClub Downgrades Amicus Therapeutics (FOLD) to SellBidaskClub Downgrades Amicus Therapeutics (FOLD) to Sell
www.americanbankingnews.com - December 9 at 6:32 PM
Amicus Therapeutics, Inc. (FOLD) CEO Sells $642,568.93 in StockAmicus Therapeutics, Inc. (FOLD) CEO Sells $642,568.93 in Stock
www.americanbankingnews.com - December 6 at 8:28 PM
Jay Barth Sells 5,000 Shares of Amicus Therapeutics, Inc. (FOLD) StockJay Barth Sells 5,000 Shares of Amicus Therapeutics, Inc. (FOLD) Stock
www.americanbankingnews.com - December 5 at 11:22 PM
ETFs with exposure to Amicus Therapeutics, Inc. : December 5, 2017ETFs with exposure to Amicus Therapeutics, Inc. : December 5, 2017
finance.yahoo.com - December 5 at 5:14 PM
Amicus Therapeutics, Inc. :FOLD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017Amicus Therapeutics, Inc. :FOLD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017
finance.yahoo.com - December 1 at 4:53 PM
$14.56 Million in Sales Expected for Amicus Therapeutics, Inc. (FOLD) This Quarter$14.56 Million in Sales Expected for Amicus Therapeutics, Inc. (FOLD) This Quarter
www.americanbankingnews.com - November 28 at 6:56 AM
Short Interest in Amicus Therapeutics, Inc. (FOLD) Increases By 7.9%Short Interest in Amicus Therapeutics, Inc. (FOLD) Increases By 7.9%
www.americanbankingnews.com - November 27 at 11:32 PM
Amicus Therapeutics, Inc. (FOLD) Receives Average Recommendation of "Buy" from AnalystsAmicus Therapeutics, Inc. (FOLD) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 16 at 3:38 AM
FY2017 EPS Estimates for Amicus Therapeutics, Inc. (FOLD) Decreased by AnalystFY2017 EPS Estimates for Amicus Therapeutics, Inc. (FOLD) Decreased by Analyst
www.americanbankingnews.com - November 13 at 3:36 AM
Amicus Therapeutics, Inc. (FOLD) Short Interest UpdateAmicus Therapeutics, Inc. (FOLD) Short Interest Update
www.americanbankingnews.com - November 12 at 1:32 AM
November Top Growth CompaniesNovember Top Growth Companies
finance.yahoo.com - November 10 at 4:59 PM
Amicus Therapeutics Announces Third Quarter 2017 Financial Results and Corporate UpdatesAmicus Therapeutics Announces Third Quarter 2017 Financial Results and Corporate Updates
finance.yahoo.com - November 9 at 3:50 AM
Amicus Therapeutics reports 3Q lossAmicus Therapeutics reports 3Q loss
finance.yahoo.com - November 9 at 3:50 AM
Is It Time To Buy Amicus Therapeutics Inc (FOLD)?Is It Time To Buy Amicus Therapeutics Inc (FOLD)?
finance.yahoo.com - November 9 at 3:50 AM
Edited Transcript of FOLD earnings conference call or presentation 8-Nov-17 1:30pm GMTEdited Transcript of FOLD earnings conference call or presentation 8-Nov-17 1:30pm GMT
finance.yahoo.com - November 9 at 3:50 AM
Amicus Therapeutics, Inc. (FOLD) Issues Quarterly  Earnings ResultsAmicus Therapeutics, Inc. (FOLD) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 8 at 4:23 PM
Should You Sell Amicus Therapeutics, Inc. (FOLD) Before Earnings? - NasdaqShould You Sell Amicus Therapeutics, Inc. (FOLD) Before Earnings? - Nasdaq
www.nasdaq.com - November 8 at 7:02 AM
Should You Sell Amicus Therapeutics, Inc. (FOLD) Before Earnings?Should You Sell Amicus Therapeutics, Inc. (FOLD) Before Earnings?
finance.yahoo.com - November 8 at 7:02 AM
Amicus Therapeutics, Inc. – Value Analysis (NASDAQ:FOLD) : November 7, 2017Amicus Therapeutics, Inc. – Value Analysis (NASDAQ:FOLD) : November 7, 2017
finance.yahoo.com - November 8 at 7:02 AM
Amicus Therapeutics, Inc. to Host Earnings CallAmicus Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 8 at 7:02 AM
Zacks: Brokerages Anticipate Amicus Therapeutics, Inc. (FOLD) to Post -$0.32 Earnings Per ShareZacks: Brokerages Anticipate Amicus Therapeutics, Inc. (FOLD) to Post -$0.32 Earnings Per Share
www.americanbankingnews.com - November 8 at 1:16 AM
Amicus Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : FOLD-US : November 6, 2017Amicus Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : FOLD-US : November 6, 2017
finance.yahoo.com - November 6 at 10:58 PM
Amicus Therapeutics, Inc. (FOLD) to Release Earnings on MondayAmicus Therapeutics, Inc. (FOLD) to Release Earnings on Monday
www.americanbankingnews.com - October 30 at 8:42 AM
Amicus Therapeutics to Announce Third Quarter 2017 Financial Results on November 8, 2017Amicus Therapeutics to Announce Third Quarter 2017 Financial Results on November 8, 2017
finance.yahoo.com - October 25 at 11:18 PM
Amicus Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : FOLD-US : October 23, 2017Amicus Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : FOLD-US : October 23, 2017
finance.yahoo.com - October 23 at 4:35 PM
Head to Head Analysis: Female Health Company (The) (VERU) versus Amicus Therapeutics (FOLD)Head to Head Analysis: Female Health Company (The) (VERU) versus Amicus Therapeutics (FOLD)
www.americanbankingnews.com - October 23 at 2:12 PM
Amicus Therapeutics, Inc. (FOLD) Expected to Announce Quarterly Sales of $9.93 MillionAmicus Therapeutics, Inc. (FOLD) Expected to Announce Quarterly Sales of $9.93 Million
www.americanbankingnews.com - October 21 at 9:26 AM
Notable Friday Option Activity: LAMR, ATI, FOLDNotable Friday Option Activity: LAMR, ATI, FOLD
www.nasdaq.com - October 20 at 7:52 PM
John F. Crowley Sells 71,735 Shares of Amicus Therapeutics, Inc. (FOLD) StockJohn F. Crowley Sells 71,735 Shares of Amicus Therapeutics, Inc. (FOLD) Stock
www.americanbankingnews.com - October 19 at 10:32 PM
Amicus Therapeutics Inc (FOLD) Chairman & CEO John F Crowley Sold $6.4 million of Shares - NasdaqAmicus Therapeutics Inc (FOLD) Chairman & CEO John F Crowley Sold $6.4 million of Shares - Nasdaq
www.nasdaq.com - October 18 at 5:38 AM
Insider Selling: Amicus Therapeutics, Inc. (FOLD) CEO Sells 449,295 Shares of StockInsider Selling: Amicus Therapeutics, Inc. (FOLD) CEO Sells 449,295 Shares of Stock
www.americanbankingnews.com - October 17 at 1:16 PM
Amicus Therapeutics, Inc. (FOLD) SVP Daphne Quimi Sells 7,000 SharesAmicus Therapeutics, Inc. (FOLD) SVP Daphne Quimi Sells 7,000 Shares
www.americanbankingnews.com - October 16 at 10:33 PM
Amicus Therapeutics, Inc. (FOLD) Director Michael Raab Sells 10,000 SharesAmicus Therapeutics, Inc. (FOLD) Director Michael Raab Sells 10,000 Shares
www.americanbankingnews.com - October 16 at 10:33 PM
Amicus Therapeutics, Inc. (FOLD) Insider Hung Do Sells 50,194 SharesAmicus Therapeutics, Inc. (FOLD) Insider Hung Do Sells 50,194 Shares
www.americanbankingnews.com - October 16 at 10:33 PM
William D. Baird III Sells 40,000 Shares of Amicus Therapeutics, Inc. (FOLD) StockWilliam D. Baird III Sells 40,000 Shares of Amicus Therapeutics, Inc. (FOLD) Stock
www.americanbankingnews.com - October 16 at 10:32 PM
Short Interest in Amicus Therapeutics, Inc. (FOLD) Drops By 10.0%Short Interest in Amicus Therapeutics, Inc. (FOLD) Drops By 10.0%
www.americanbankingnews.com - October 13 at 1:32 AM
Amicus Therapeutics, Inc. (FOLD) Downgraded by Zacks Investment Research to HoldAmicus Therapeutics, Inc. (FOLD) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - October 12 at 9:30 PM
These Biotech Stocks Are Pricey, but Investors Can Still Buy ThemThese Biotech Stocks Are Pricey, but Investors Can Still Buy Them
finance.yahoo.com - October 10 at 9:30 PM
Bank of America Corporation Boosts Amicus Therapeutics, Inc. (FOLD) Price Target to $20.00Bank of America Corporation Boosts Amicus Therapeutics, Inc. (FOLD) Price Target to $20.00
www.americanbankingnews.com - October 8 at 8:34 PM
Amicus Therapeutics, Inc. (FOLD) Earns Neutral Rating from Goldman Sachs Group, Inc. (The)Amicus Therapeutics, Inc. (FOLD) Earns Neutral Rating from Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - October 6 at 9:08 PM
Opinion: Harry Boxers four stocks that are breaking out this week - MarketWatchOpinion: Harry Boxer's four stocks that are breaking out this week - MarketWatch
www.marketwatch.com - October 5 at 10:58 PM
Amicus Therapeutics (FOLD) Soars: Stock Adds 9.2% in SessionAmicus Therapeutics (FOLD) Soars: Stock Adds 9.2% in Session
finance.yahoo.com - October 5 at 5:57 PM
Amicus Therapeutics, Inc. (FOLD) Given Buy Rating at Chardan CapitalAmicus Therapeutics, Inc. (FOLD) Given Buy Rating at Chardan Capital
www.americanbankingnews.com - October 5 at 10:08 AM
Todays Research Reports on Stocks to Watch: Amicus Therapeutics and CytomX TherapeuticsToday's Research Reports on Stocks to Watch: Amicus Therapeutics and CytomX Therapeutics
finance.yahoo.com - October 5 at 8:53 AM

SEC Filings

Amicus Therapeutics (NASDAQ:FOLD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Amicus Therapeutics (NASDAQ:FOLD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Amicus Therapeutics (NASDAQ FOLD) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.